Dr. Rezvani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
300 Pasteur Dr
Stanford, CA 94305Phone+1 650-723-4000
Summary
- I am a physician and clinical researcher at Stanford University, specializing in hematopoietic cell transplantation and cellular therapy.
Education & Training
University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2007- University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2006
Duke University HospitalResidency, Internal Medicine, 2001 - 2004
Lewis Katz School of Medicine at Temple UniversityClass of 2001
Certifications & Licensure
CA State Medical License 2014 - 2025
WA State Medical License 2004 - 2015
NC State Medical License 2001 - 2004- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome Start of enrollment: 2006 Dec 01
- Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Start of enrollment: 2009 Feb 01
- Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation Start of enrollment: 2012 May 01
- Join now to see all
Publications & Presentations
PubMed
- 43 citationsTransplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipientsEverett Meyer, Ginna G. Laport, Bryan J. Xie, Kate MacDonald, Kartoosh Heydari
JCI Insight. 2019-05-16 - 198 citationsIncreasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United StatesLori Muffly, Marcelo C. Pasquini, Michael Martens, Ruta Brazauskas, Xiaochun Zhu
Blood. 2017-08-31 - 223 citationsReduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors.Abraham S. Kanate, Alberto Mussetti, Mohamed A. Kharfan-Dabaja, Kwang Woo Ahn, Alyssa DiGilio
Blood. 2016-02-18
Abstracts/Posters
- Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel AgentsAndrew R Rezvani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Com...Andrew R Rezvani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Study Predicts Who May Benefit from CAR-T Cell Therapy for Blood CancersAugust 2nd, 2021- Nevada Cancer Survivor Found to Have Two Different Sets of DNA After Bone Marrow Transplant 4 Years AgoDecember 10th, 2019
- After Bone Marrow Transplant, Patient's Blood Contains Only Donor's DNA: Three Months After a Nevada Man Received a Bone Marrow Transplant, Tests Revealed the DNA in His Blood Had Been Replaced by the DNA of His Donor, a Man He Barely Knew, According t...December 9th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
